The Center had issued a letter in 2023 asking licensing authorities of states and union territories not to take action against Ayurvedic companies promoting their products in violation of Section 170 of the Drugs and Cosmetics Rules, 1945. defended in court. live low It was reported on Tuesday.
[Rule170ofthe1945RulesprohibitsadvertisingofAyurvedicSiddhaandUnanidrugswithoutpriorpermissionfromthelicensingauthority[1945年規則の規則170は、認可当局からの事前の許可なしに、アーユルヴェーダ、シッダ、ウナニの薬物の広告を禁止しています。
The filing was made by the joint secretary of the Ministry of AYUSH (Ayurveda, Yoga, Naturopathy, Unani, Siddha and Homeopathy) as part of contempt proceedings against Patanjali co-founder yoga guru Ramdev and Patanjali managing director Balkrishna. It was made in an affidavit filed. Placing misleading advertisements in violation of the Objectionable Advertising Law on Drugs and Magical Remedies.
According to the Centre’s affidavit, the letter dated August 29, 2023 was issued on the recommendation of Ayurveda Siddha Unani Drug Technical Advisory Committee dated May 25, 2023 under Rule 170. suggests that it should be removed from the Drugs and Cosmetics Regulations. 1945.
The Center also pointed out that petitions have been filed in the Delhi, Bombay and Kerala High Courts challenging this provision.
In order to “avoid confusion and prevent inevitable litigation”, the ministry has issued a warning to licensing authorities in all states and union territories “not to take any action under Section 170 of the Drugs and Cosmetic Products Rules, 1945”. A letter was issued instructing the government to do so. As the final notification is currently being processed. ”
He added that the final gazette notification will take some more time.
After the Supreme Court’s April 16 order, Patanjali Ayurveda’s co-founders told the court that even though they had assured the court that they would stop advertising products that made dubious claims, He apologized for the mistake in holding the press conference.
